Genmab A/S: Genmab Showcases Data From Robust Development Pr

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage

Related Keywords

Japan , Louisiana , United States , New Orleans , Tokyo , Denmark , Copenhagen , Køavn , New Jersey , Netherlands , American , David Freundel , Judith Klimovsky , Andrew Carlsen , Exposition Of The American Society Hematology , Product Communications , Macrophage Propertiesj Immunol , Data From The Observational National Lymphocare Study , Twitter , National Institutes Of Health , Drug Administration , Exchange Commission , Leukaemia Foundation , Development Of Novel Anti , European Medicines Agency , Lymphoma Research Foundation , Annual Meeting , American Society , Executive Vice President , Chief Development Officer , Diffuse Largeb Cell Lymphoma , Follicular Lymphoma , Biologics License Application , Priority Review , Marketing Authorization Application , Forward Looking Statements , Media Release , Annual Report , Y Shaped Genmab , Diffuse Largeb Cell , Stat Facts , Accessed November , Research Foundation , Subsequent Therapy , Data From , Observational National Lymphocare , Treatment Patterns , Patients With Diffuse Largeb Cell Lymphoma , Clinically Utilized , Directed Antibodies , Macrophage Properties , Novel Anti Cd , Cell Surface , Cancer Sci , Investor Relations , Vice President , Genmab , Howcases , Data , Rom , Obust , Development , Program , Valuating , Epcoritamab , Uobody , D3xcd20 , Patients , Cross , Road , Orange , Fell , Lymphomas , 4th , Nnual , Meeting ,